Speakers

Dr Derek Connolly Consultant Cardiologist  at Birmingham City Hospital, Birmingham
Dr Dermot Neely Retired Lipidologist, HEART UK Trustee

Learning objectives

• Triglycerides as a target for treatment
• How treatment can improve outcomes
• The role of highly-purified omega-3 fatty acid (icosapent ethyl) to treat hypertriglyceridaemia
• Early versus later omega-3 fatty acid studies
• REDUCE-IT – randomised, double-blind, placebo-controlled trial looking at cardiovascular risk reduction with icosapent ethyl for hypertriglyceridaemia

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

1. NIH. High blood triglycerides. 2023. Available at: https://www.nhlbi.nih.gov/health/high-blood-triglycerides#:~:text=Triglycerides%20are%20a%20type%20of,and%20other%20fats%20you%20eat  (accessed March 2024)
2. NICE. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [TA805] 2022. Available at: https://www.nice.org.uk/guidance/ta805. (accessed March 2024)
3. Padda IS et al. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK592399/ (accessed March 2024)
4. Heart UK. Type 3 hyperlipidaemia. Available at: https://www.heartuk.org.uk/genetic-conditions/type-3-hyperlipidaemia (accessed March 2024)
5. Heart UK. Triglycerides. 2024. Available at: https://www.heartuk.org.uk/cholesterol/triglycerides (accessed March 2024)
6. Bhatt DL et al. N Engl J Med 2019;380:11–22
7. Benuck I et al. Endotext [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK395574/ (accessed March 2024)

Speakers

Professor Terry McCormack Professor of Primary Care Cardiovascular Medicine, Hull York Medical School
Dr Peter Green GP, High Parks Medical Practice, University of Kent

Learning objectives

• Understand the national guidelines for lipid management for primary and secondary prevention of CVD
• Understand the lipid targets for prevention of CVD
• Update knowledge on assessing cholesterol levels and understand why guidelines now include measurements for non-high-density lipoprotein cholesterol (non-HDL-C)
• Understand the national guidelines for CVD risk assessment and follow up
• Recognise the importance and use of smart open-access data tools CVDPREVENT and CVDACTION

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

1. NHS England. Summary of national guidance for lipid management for primary and secondary prevention of CVD. 2022. Available from: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf (accessed April 2024)
2. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. 2023. Available from: https://www.nice.org.uk/guidance/ng238/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-66143902851781 (accessed April 2024)
3. Reynolds TM et al. Vasc Health Risk Manag 2021;17:227–37
4. Guo L-L et al. Front Cardiovasc Med 2021;8:649181
5. Liu M-M et al. Ann Transl Med 2021;9:386
6. UCLPartners Health Innovation. CVDACTION: Transforming the prevention of cardiovascular disease. Available from: https://uclpartners.com/our-priorities/cardiovascular/cvdaction-transforming-the-prevention-of-cardiovascular-disease/ (accessed April 2024)
7. Ma H, Shieh K-J. Am J Sci 2006;2:46–50
8. Nelson RH. Prim Care 2013;40:195–211
9. Taskinen MR, Borén J. Atherosclerosis 2015;239:483–95
10. Chiesa ST et al. Eur Heart J 2019;40:3559–66
11. Reiss AB et al. Am J Kidney Dis 2015;66:1071–82

Speakers

Dr Rani Khatib Consultant Pharmacist in Cardiology & Cardiovascular Research, Leeds Teaching Hospitals NHS Trust
Dr Dermot Neely Specialist Adviser on lipids to Academic Health Science Network – North-East and North Cumbria

Learning objectives

• Understand the national lipid management pathway, and primary and secondary prevention of cardiovascular disease

• Understand when non-statin therapeutic approaches may be indicated in clinical practice

• Identify the patient groups who may benefit from non-statin lipid-lowering therapeutic options

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

1. NHS England. Improving lipid management to reduce cardiovascular disease and save lives. 2023. Available at: https://www.england.nhs.uk/long-read/improving-lipid-management-to-reduce-cardiovascular-disease-and-save-lives/ (accessed February 2024)
2. NICE. CKS. Lipid modification – CVD prevention: Statins. 2023. Available at: https://cks.nice.org.uk/topics/lipid-modification-cvd-prevention/prescribing-information/statins/ (accessed February 2024)
3. NHS England. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD. Available at: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf (accessed February 2024)
4. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2024)